NIA-AA staging of preclinical Alzheimer disease: Discordance and concordance of CSF and imaging biomarkers

Neurobiology of Aging

Volumn 44, Issue , 2016, Pages 1-8

  Vos, Stephanie J B ^a   Gordon, Brian A ^b   Su, Yi ^b   Visser, Pieter Jelle ^a,c   Holtzman, David M ^b   Morris, John C ^b   Fagan, Anne M ^b   Benzinger, Tammie L S ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aging; Alzheimer's disease; Amyloid; Biomarkers; Cerebrospinal fluid; Comorbidities; Diagnosis; MRI; Neuroimaging; Neuronal injury; PET; Prognosis

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B; TAU PROTEIN; TAURINE TRANSPORTER; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BETA AMYLOIDOSIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; NERVE CELL LESION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VERY ELDERLY; DIAGNOSTIC IMAGING; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX;

EID: 84969513778     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.03.025     Document Type: Article

References (47)

1. Aisen P.S., Vellas B., Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat. Rev. Drug Discov. 2013, 12:324.
2. Alexopoulos P., Kriett L., Haller B., Klupp E., Gray K., Grimmer T., Laskaris N., Förster S., Perneczky R., Kurz A., Drzezga A., Fellgiebel A., Yakushev I. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. Alzheimers Dement. 2014, 10:684-689.
3. Bateman R.J., Xiong C., Benzinger T.L.S., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012, 367:795-804.
4. Berg L., Mckeel D.W., Mille J., Storandt M., Rubin E.H., Morris J.C., Baty J., Norton J., Goate A.M., Price J.L., Gearing M., Mirra S.S., Saunders A.M., Miller J.P., Storandt M., Rubin E.H., Morris J.C., Baty J., Coats M., Norton J., Goate A.M., Price J.L., Gearing M., Mirra S.S., Saunders A.M. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein e genotype. Arch. Neurol. 1998, 55:326-335.
5. Buckner R.L., Head D., Parker J., Fotenos A.F., Marcus D., Morris J.C., Snyder A.Z. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004, 23:724-738.
6. Caroli A., Prestia A., Galluzzi S., Ferrari C., Van Berckel B., Teunissen C., Wall A.E., Carter S.F., Schöll M., Redolfi A., Nordberg A., Drzezga A., Frisoni G.B. Mild cognitive impairment with suspected nonamyloid pathology (SNAP) Prediction of progression. Neurology 2015, 84:508-515.
7. Cohen A.D., Klunk W.E. Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol. Dis. 2014, 72:117-122.
8. Cohen O.S., Chapman J., Korczyn A.D., Warman-Alaluf N., Nitsan Z., Appel S., Kahana E., Rosenmann H. CSF tau correlates with CJD disease severity and cognitive decline. Acta Neurol. Scand. 2016, 133:119-123.
9. De Meyer G., Shapiro F., Vanderstichele H., Vanmechelen E., Engelborghs S., De Deyn P.P., Coart E., Hansson O., Minthon L., Zetterberg H., Blennow K., Shaw L., Trojanowski J.Q. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 2010, 67:949-956.
10. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 2006, 59:512-519.
11. Fischl B., van der Kouwe A., Destrieux C., Halgren E., Segonne F., Salat D.H., Busa E., Seidman L.J., Goldstein J., Kennedy D., Caviness V., Makris N., Rosen B., Dale A.M. Automatically parcellating the human cerebral Cortex. Cereb. Cortex 2004, 14:11-22.
12. Hassenstab J., Chasse R., Grabow P., Benzinger T.L., Fagan A.F., Xiong C., Jasielec M., Grant E., Morris J.C. Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. Neurobiol. Aging 2016, (In press), http://dx.doi.org/10.1016/j.neurobiolaging.2016.03.014.
13. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., Deyn P.P.D., Bancher C., Cras P., Wiltfang J., Mehta P.D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H. Improved discrimination of AD patients using -amyloid(1-42) and tau levels in CSF. Neurology 1999, 52:1555.
14. Ivanoiu A., Dricot L., Gilis N., Grandin C., Lhommel R., Quenon L., Hanseeuw B. Classification of non-demented patients attending a Memory Clinic using the new diagnostic criteria for Alzheimer's with disease-related biomarkers. J. Alzheimers Dis. 2015, 43:835-847.
15. Jack C.R., Dickson D.W., Parisi J.E., Xu Y.C., Cha R.H., O'Brien P.C., Edland S.D., Smith G.E., Boeve B.F., Tangalos E.G., Kokmen E., Petersen R.C. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58:750-757.
16. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
17. Jack C.R., Knopman D.S., Weigand S.D., Wiste H.J., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Rocca W.A., Boeve B.F., Petersen R.C. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 2012, 71:765-775.
18. Jack C.R., Vemuri P., Wiste H.J., Weigand S.D., Aisen P.S., Trojanowski J.Q., Shaw L.M., Bernstein M.A., Petersen R.C., Weiner M.W., Knopman D.S. Evidence for ordering of Alzheimer disease biomarkers. Arch. Neurol. 2011, 68:1526-1535.
19. Jack C.R., Wiste H.J., Knopman D.S., Vemuri P., Mielke M.M., Weigand S.D., Senjem M.L., Gunter J.L., Lowe V., Gregg B.E., Pankratz V.S., Petersen R.C. Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 2014, 82:1605-1612.
20. Jack C.R., Wiste H.J., Weigand S.D., Knopman D.S., Mielke M.M., Vemuri P., Lowe V., Senjem M.L., Gunter J.L., Reyes D., Machulda M.M., Roberts R., Petersen R.C. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain 2015, 138:3747-3759.
21. Johnson D.K., Storandt M., Morris J.C., Langford Z.D., Galvin J.E. Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging. Neurology 2008, 71:1783-1789.
22. Kapaki E., Paraskevas G.P., Zalonis I., Zournas C. CSF tau protein and β-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur. J. Neurol. 2003, 10:119-128.
23. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
24. Knopman D.S., Jack C.R., Wiste H.J., Weigand S.D., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Boeve B.F., Petersen R.C. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582.
25. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990, 10:740-747.
26. Mattsson N., Insel P.S., Donohue M., Landau S., Jagust W.J., Shaw L.M., Trojanowski J.Q., Zetterberg H., Blennow K., Weiner M.W. Independent information form cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. Brain 2015, 138:772-783. Alzheimer's Disease Neuroimaging Initiave.
27. Mattsson N., Insel P.S., Landau S., Jagust W., Donohue M., Shaw L.M., Trojanowski J.Q., Zetterberg H., Blennow K., Weiner M. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann. Clin. Transl. Neurol. 2014, 1:534-543.
28. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939.
29. Mormino E.C., Betensky R.A., Hedden T., Schultz A.P., Amariglio R.E., Rentz D.M., Johnson K.A., Sperling R.A. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014, 71:1379.
30. Morris J.C. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
31. Mulder C., Verwey N.A., van der Flier W.M., Bouwman F.H., Kok A., van Elk E.J., Scheltens P., Blankenstein M.A. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem. 2010, 56:248-253.
32. Petersen R.C., Aisen P., Boeve B.F., Geda Y.E., Ivnik R.J., Knopman D.S., Mielke M., Pankratz V.S., Roberts R., Rocca W.A., Weigand S., Weiner M., Wiste H., Jack C.R. Mild cognitive impairment due to Alzheimer disease in the community. Ann. Neurol. 2013, 74:199-208.
33. Pizzie R., Hindman H., Roe C.M., Head D., Grant E., Morris J.C., Hassenstab J.J. Physical activity and cognitive trajectories in cognitively normal adults: the adult children study. Alzheimer Dis. Assoc. Disord. 2014, 28:50-57.
34. Roe C.M., Fagan A.M., Grant E.A., Hassenstab J., Moulder K.L., Maue Dreyfus D., Sutphen C.L., Benzinger T.L.S., Mintun M.A., Holtzman D.M., Morris J.C. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013, 80:1784-1791.
35. Rousset O.G., Ma Y., Evans A.C. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998, 39:904-911.
36. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer' disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
37. Spiegel J., Pirraglia E., Osorio R.S., Glodzik L., Li Y., Tsui W., Saint Louis L.A., Randall C., Butler T., Xu J., Zinkowski R.P., Zetterberg H., Fortea J., Fossati S., Wisniewski T., Davies P., Blennow K., de Leon M.J. Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease. J. Alzheimers. Dis. 2015, 49:93-100.
38. Su Y., Blazey T.M., Snyder A.Z., Raichle M.E., Marcus D.S., Ances B.M., Bateman R.J., Cairns N.J., Aldea P., Cash L., Christensen J.J., Friedrichsen K., Hornbeck R.C., Farrar A.M., Owen C.J., Mayeux R., Brickman A.M., Klunk W., Price J.C., Thompson P.M., Ghetti B., Saykin A.J., Sperling R.A., Johnson K.A., Schofield P.R., Buckles V., Morris J.C., Benzinger T.L.S. Partial volume correction in quantitative amyloid imaging. Neuroimage 2015, 107:55-64.
39. Su Y., D'Angelo G.M., Vlassenko A.G., Zhou G., Snyder A.Z., Marcus D.S., Blazey T.M., Christensen J.J., Vora S., Morris J.C., Mintun M.A., Benzinger T.L.S. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One 2013, 8:e73377.
40. Sutphen C.L., Jasielec M.S., Shah A.R., Macy E.M., Xiong C., Vlassenko A.G., Benzinger T.L.S., Stoops E.E.J., Vanderstichele H.M.J., Brix B., Darby H.D., Vandijck M.L.J., Ladenson J.H., Morris J.C., Holtzman D.M., Fagan A.M. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 2015, 72:1029-1042.
41. Toledo J.B., Bjerke M., Da X., Landau S.M., Foster N.L., Jagust W., Jack C., Weiner M., Davatzikos C., Shaw L.M., Trojanowski J.Q. Nonlinear association between cerebrospinal fluid and florbetapir F-18 β-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol. 2015, 72:571.
42. Toledo J.B., Weiner M.W., Wolk D.A., Da X., Chen K., Arnold S.E., Jagust W., Jack C., Reiman E.M., Davatzikos C., Shaw L.M., Trojanowski J.Q. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol. Commun. 2014, 2:26.
43. Tsitsopoulos P.P., Marklund N. Amyloid-β Peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies. Front. Neurol. 2013, 4:79.
44. Van Harten A.C., Smits L.L., Teunissen C.E., Visser P.J., Koene T., Blankenstein M.A., Scheltens P., Van Der Flier W.M. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 2013, 81:1409-1416.
45. Villemagne V.L., Fodero-Tavoletti M.T., Masters C.L., Rowe C.C. Tau imaging: early progress and future directions. Lancet Neurol. 2015, 14:114-124.
46. Vos S.J., Xiong C., Visser P.J., Jasielec M.S., Hassenstab J., Grant E.A., Cairns N.J., Morris J.C., Holtzman D.M., Fagan A.M. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013, 12:957-965.
47. Whitwell J.L., Jack C.R., Parisi J.E., Senjem M.L., Knopman D.S., Boeve B.F., Rademakers R., Baker M., Petersen R.C., Dickson D.W., Josephs K.A. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?. Neurology 2010, 75:2212-2220.